Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19018
Title: Support for the use of objective comorbidity indices in the assessment of noncancer death risk in prostate cancer patients.
Austin Authors: Ng, Sweet Ping ;Duchesne, Gillian;Tai, Keen-Hun;Foroudi, Farshad ;Kothari, Gargi;Williams, Scott
Affiliation: Department of Radiation Oncology, Austin Health, Heidelberg, Victoria, Australia
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
Issue Date: Mar-2017
metadata.dc.date: 2016-12-18
Publication information: Prostate international 2017; 5(1): 8-12
Abstract: Prostate cancer management involves a balance between the risks of cancer death against those from other causes. To evaluate the performance of several comorbidity indices in predicting comorbid death in a prostate cancer radiotherapy cohort. 2,131 men with localised prostate cancer treated with radical radiotherapy between 1999 and 2007 were studied. Tumour features, androgen deprivation usage, age, number of prescription medications (PMN) and Adult Comorbidity Evaluation-27 Index (ACE-27) were recorded. Death from prostate cancer (DPC) and death from other causes (DOC) were analysed as competing causes of death using a competing risks model, with discrimination assessed using the concordance index. ACE-27 scores correlated with patient's PMN (median PMN = 2). Tumour features were independent of ACE-27 scores. Estimated cumulative incidences of DOC and DPC at 10 years were 16.4% and 7.7% respectively. In the low/intermediate risk group (n = 1026) there was a 3.4-fold predominance of DOC inside 10 years (cumulative incidence: 15.8% DOC vs 3.4% DPC). High-risk men had approximately equal rates of DPC and DOC at 10 years. Multivariable analysis showed age, ACE-27 score ≥ 1 and PMN to have significant associations with DOC (P < 0.002 for all). A multivariable model incorporating all 3 variables resulted in C-Index = 0.646. Age, ACE-27 score and PMN act as independent prognostic factors for DOC in prostate cancer patients and can improve patient's life expectancy prediction.
URI: http://ahro.austin.org.au/austinjspui/handle/1/19018
DOI: 10.1016/j.prnil.2016.12.001
ORCID: 0000-0001-8387-0965
PubMed URL: 28352617
ISSN: 2287-8882
Type: Journal Article
Subjects: Comorbidity
Prostate cancer
Radiotherapy
Appears in Collections:Journal articles

Show full item record

Page view(s)

2
checked on Dec 6, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.